Pharmacogenetics and anticoagulant therapy

Journal of Thrombosis and Thrombolysis

Volumn 16, Issue 1-2, 2003, Pages 73-78

  Gage, Brian F ^a   Eby, Charles S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Pharmacogenetics; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; COUMARIN DERIVATIVE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; PHENYTOIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

AGE; ALGORITHM; ANALYSIS OF VARIANCE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BODY SURFACE; DOSE RESPONSE; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANCE; FREQUENCY ANALYSIS; GENE FREQUENCY; GENE MUTATION; HUMAN; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MOUSE; NONHUMAN; PATIENT MONITORING; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTICOAGULANTS; HUMANS; PHARMACOGENETICS;

EID: 1842627562     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:THRO.0000014598.24114.62     Document Type: Article

References (64)

1. Gage BF, Cardinalli AB, Albers GW, Owens D. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839-1845.
2. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994;154:1449-1457.
3. Van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: An individual patient meta-analysis. JAMA 2002;288: 2441-2448.
4. Olsson SB for the Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlledd trial. Lancet 2003;362:1691-1698.
5. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002;347:969-974.
6. van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 Study): A randomised controlled trial. Lancet 2002;360: 109-113.
7. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348: 1425-1434.
8. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002;137:648-655.
9. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: A prospective controlled randomized study. Arch Intern Med 2002;162:1966-1971.
10. Redman AR. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 2001;21:235-242.
11. Azar AJ, Deckers JW, Rosendaal FR, et al. Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients. Thromb Hemostas 1994;72:347-351.
12. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-1698.
13. Landefeld SC, Beyth R. Anticoagulant-related bleeding: Clinical epidemiology, prediction and prevention. Am J Med 1993;95:315-328.
14. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 1993;118:511-520.
15. Douketis JD, Foster GA, Crowther MA, et al. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med 2000;160:3431-3436.
16. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A Randomized, Controlled Trial. Ann Intern Med 2000;133:687-695.
17. Fennerty A, Dolben J, Thomas P, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) 1984;288:1268-1270.
18. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-136.
19. Gedge J, Orme S, Hampton KK, et al. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 2000;29:31-34.
20. O'Connell MB, Kowal PR, Allivato CJ, Repka TL. Evaluation of warfarin initiation regimens in elderly inpatients. Pharmacotherapy 2000;20:923-930.
21. Roberts GW, Druskeit T, Jorgensen LE, et al. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. Aust N Z J Med 1999;29:731-736.
22. Oates A, Jackson PR, Austin CA, Channer KS. A new regimen for starting warfarin therapy in out-patients. Br J Clin Pharmacol 1998;46:157-161.
23. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A Randomized, Double-Blind, Controlled Trial. Ann Intern Med 2003;138:714-719.
24. Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: Analysis of data from the general practice research database. Heart 2001;86:284-288.
25. Roberts G, Trine H, Nielsen CB, et al. Assessment of an age-adjusted warfarin initiation protocol. Ann Pharmacother 2003;37:799-803.
26. Beyth RJ, Milligan PE, Gage BF. Risk factors for bleeding in patients taking coumarins. Curr Hem Reports 2002;1:41-49.
27. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105: 91-99.
28. Wells PS, Forgie MA, Simms M, et al. The outpatient bleeding risk index: Validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 2003;163:917-920.
29. Kuijer PM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999;159:457-460.
30. Gage BF, Yan Y, Milligan PE, et al. Validation of clinical classification schemes for predicting hemorrhage: Results from the national registry of atrial fibrillation (abstract). J Thromb Thrombolysis 2003.
31. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002;36:1512-1517.
32. Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004;91:87-94.
33. Gurwitz J, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901-904.
34. Routledge P, Chapman P, Davies D, Rawlins M. Factors affecting warfarin requirements: A prospective population study. Eur J Clin Pharmacol 1979;15:319-322.
35. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992;45:704-706.
36. Wynne H, Cope L, Kelly P, et al. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 1995;40:203-207.
37. Shepherd AM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977;4:315-320.
38. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin-Nature or nurture? Clin Pharmacol Ther 2001;70:159-164.
39. Mungall DR, Ludden TM, Marshall J, et al. Population kinetics of racemic warfarin. Journal of Pharmacokinetics and Biopharmaceutics 1985;13:213-227.
40. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000;109:481-488.
41. Sanoski CA, Bauman JL. Clinical observations with the amiodarone/warfarin interaction: Dosing relationships with long-term therapy. Chest 2002;121:19-23.
42. Ristola P, Pyorala K. Determinants of the response to coumarin anticoagulants in patients with acute myocardial infarction. Acta Med Scand 1972;192:183-188.
43. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119:22S-38S.
44. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002;72:702-710.
45. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000;84:775-778.
46. Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361-367.
47. Takahashi H, Kashima T, Nomoto S, et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: Catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 1998;8:356-373.
48. Tabrizi AR, Zehnbauer BA, Borecki IB, et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 2002;194:267-273.
49. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719.
50. Kaminsky LS, de Morais SM, Faletto MB, et al. Correlation of human cytochrome P4502C substrate specificities with primary structure: Warfarin as a probe. Mol Pharmacol 1993;43:234-239.
51. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 1992;267:83-90.
52. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-1819.
53. Imai J, Ieiri I, Mamiya K, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: Genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000;10:85-89.
54. Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 2001;60:382-387.
55. Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001;11:803-808.
56. Leung AY, Chow HC, Kwong YL, et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001;98:2584-2587.
57. Rettie AE, Tai G, Veenstra DL, et al. CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians. Blood 2003;101:2896-2897.
58. Wallace ME, MacSwiney FJ. A major gene controlling warfarin-resistance in the house mouse. J Hyg (Lond) 1976;76:173-181.
59. Greaves JH, Ayres P. Linkages between genes for coat colour and resistance to warfarin in Rattus norvegicus. Nature 1969;224:284-285.
60. Kohn MH, Pelz HJ, Wayne RK. Natural selection mapping of the warfarin-resistance gene. Proc Natl Acad Sci USA 2000;97:7911-7915.
61. Kohn MH, Pelz HJ. A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. Blood 2000;96:1996-1998.
62. Hulse ML. Warfarin resistance: Diagnosis and therapeutic alternatives. Pharmacotherapy 1996;16:1009-1017.
63. Kohn MH, Pelz HJ, Wayne RK. Locus-specific genetic differentiation at Rw among warfarin-resistant rat (Rattus norvegicus) Populations. Genetics 2003;164:1055-1070.
64. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2000;2:E29.